Yina Diao

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.

Binghe Xu, Yongmei Yin, Ying Fan et al. · Journal of Clinical Oncology · 2024 · 45 citations

Medicine, Oncology, Pharmacology +17

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

Yongmei Yin, Ying Fan, Quchang Ouyang et al. · Nature Medicine · 2025 · 45 citations

Medicine, Oncology, Pharmacology +14

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, <i>EGFR</i> -Mutated Advanced NSCLC

Wenfeng Fang, Lin Wu, Xiangjiao Meng et al. · New England Journal of Medicine · 2025 · 40 citations

Medicine, Oncology, Pharmacology +17

SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.

Wen‐Feng Fang, Ying Cheng, Zhendong Chen et al. · Journal of Clinical Oncology · 2023 · 32 citations

Medicine, Oncology, Pharmacology +17

Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i> -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Wen‐Feng Fang, Xingya Li, Qiming Wang et al. · BMJ · 2025 · 31 citations · Full text

Medicine, Oncology, Pharmacology +16